Zacks: Analysts Set $31.00 Price Target for Odonate Therapeutics Inc (NASDAQ:ODT)

Odonate Therapeutics Inc (NASDAQ:ODT) has earned an average broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy recommendation.

Brokers have set a twelve-month consensus price target of $31.00 for the company and are expecting that the company will post ($1.17) EPS for the current quarter, according to Zacks. Zacks has also given Odonate Therapeutics an industry rank of 68 out of 256 based on the ratings given to its competitors.

A number of equities research analysts have weighed in on ODT shares. ValuEngine downgraded Odonate Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, April 18th. Zacks Investment Research raised Odonate Therapeutics from a “sell” rating to a “hold” rating and set a $22.00 target price for the company in a research report on Tuesday, April 30th. Finally, Cowen reaffirmed a “buy” rating on shares of Odonate Therapeutics in a research report on Monday, June 3rd.

ODT traded down $0.36 on Tuesday, hitting $24.52. 176,027 shares of the company were exchanged, compared to its average volume of 66,096. Odonate Therapeutics has a 12 month low of $11.54 and a 12 month high of $28.57. The firm has a market capitalization of $655.91 million, a PE ratio of -6.74 and a beta of 0.60.

Odonate Therapeutics (NASDAQ:ODT) last released its quarterly earnings data on Thursday, April 25th. The company reported ($1.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.24) by $0.08. On average, equities research analysts anticipate that Odonate Therapeutics will post -4.43 earnings per share for the current year.

In related news, CEO Kevin C. Tang purchased 93,692 shares of the stock in a transaction that occurred on Wednesday, June 5th. The shares were bought at an average price of $24.92 per share, with a total value of $2,334,804.64. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Kevin C. Tang bought 76,308 shares of the stock in a transaction on Friday, June 7th. The shares were acquired at an average cost of $27.36 per share, for a total transaction of $2,087,786.88. The disclosure for this purchase can be found here. 49.00% of the stock is currently owned by insiders.

Institutional investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp boosted its position in shares of Odonate Therapeutics by 3.6% during the 3rd quarter. Bank of New York Mellon Corp now owns 84,341 shares of the company’s stock worth $1,637,000 after purchasing an additional 2,915 shares in the last quarter. BlackRock Inc. increased its stake in shares of Odonate Therapeutics by 1.4% during the 3rd quarter. BlackRock Inc. now owns 338,825 shares of the company’s stock valued at $6,576,000 after acquiring an additional 4,566 shares during the last quarter. Vanguard Group Inc. increased its position in Odonate Therapeutics by 18.5% during the 3rd quarter. Vanguard Group Inc. now owns 316,733 shares of the company’s stock worth $6,148,000 after purchasing an additional 49,528 shares in the last quarter. Vanguard Group Inc increased its position in Odonate Therapeutics by 18.5% during the 3rd quarter. Vanguard Group Inc now owns 316,733 shares of the company’s stock worth $6,148,000 after purchasing an additional 49,528 shares in the last quarter. Finally, TD Asset Management Inc. increased its position in Odonate Therapeutics by 60.8% during the 4th quarter. TD Asset Management Inc. now owns 17,962 shares of the company’s stock worth $253,000 after purchasing an additional 6,793 shares in the last quarter. 91.48% of the stock is currently owned by hedge funds and other institutional investors.

About Odonate Therapeutics

Odonate Therapeutics, Inc, a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with locally advanced or metastatic breast cancer. The company was founded in 2013 and is based in San Diego, California.

Recommended Story: How Buying a Call Option Works

Get a free copy of the Zacks research report on Odonate Therapeutics (ODT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Odonate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odonate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.